Literature DB >> 12095148

Effect of continuous subcutaneous administration of a low dose of G-CSF on stem cell mobilization in healthy donors: a feasibility study.

Junko Tanaka1, Takaaki Miyake, Tadashi Shimizu, Toshio Wakayama, Michihiro Tsumori, Kunio Koshimura, Yoshio Murakami, Yuzuru Kato.   

Abstract

We investigated the effects of low-dose granulocyte colony-stimulating factor (G-CSF) on the mobilization of stem cells in 6 healthy subjects. When G-CSF was administered by continuous subcutaneous infusion at a rate of 72 microg/day for 5 days, the numbers of white blood cells and granulocytes rapidly increased to maximal levels. CD34+ cells were mobilized to the peripheral blood in 3 days, and the maximal level was reached 4 or 5 days after the start of treatment. We attempted to determine whether the levels of mobilized stem cells that we could obtain using this method would be sufficient for peripheral blood stem cell transplantation. Two of the 6 subjects complained of mild bone pain 4 or 5 days after the start of treatment, but the pain did not affect their daily activities. Only 1 abnormal result (for serum alkaline phosphatase) was found in the laboratory data. The present preliminary results have provided us with a framework for a prospective study comparing low-dose continuous infusion with conventional mobilization procedures.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095148     DOI: 10.1007/bf02982111

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

1.  [Effect of lenograstim (glycosylated recombinant human granulocyte-colony stimulating factor) on peripheral blood stem cell mobilization in healthy volunteers].

Authors:  A Ohnishi; M Uchino; S Asano
Journal:  Rinsho Ketsueki       Date:  2000-03

2.  Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor.

Authors:  F Falzetti; F Aversa; O Minelli; A Tabilio
Journal:  Lancet       Date:  1999-02-13       Impact factor: 79.321

3.  Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.

Authors:  A M Cavallaro; K Lilleby; I Majolino; R Storb; F R Appelbaum; S D Rowley; W I Bensinger
Journal:  Bone Marrow Transplant       Date:  2000-01       Impact factor: 5.483

4.  Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF.

Authors:  M Höglund; B Smedmyr; B Simonsson; T Tötterman; M Bengtsson
Journal:  Bone Marrow Transplant       Date:  1996-07       Impact factor: 5.483

Review 5.  [Mobilization and collection of peripheral blood stem cells].

Authors:  C Shimazaki; E Ashihara
Journal:  Rinsho Ketsueki       Date:  1996-07

6.  Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF.

Authors:  F Liu; J Poursine-Laurent; D C Link
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

7.  Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor.

Authors:  J E Layton; H Hockman; W P Sheridan; G Morstyn
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

8.  A randomised study of allogeneic transplantation with stem cells from blood or bone marrow.

Authors:  D Heldal; G Tjønnfjord; L Brinch; D Albrechtsen; T Egeland; R Steen; B G Solheim; S A Evensen
Journal:  Bone Marrow Transplant       Date:  2000-06       Impact factor: 5.483

9.  Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells.

Authors:  D F Stroncek; M E Clay; M L Petzoldt; J Smith; W Jaszcz; F B Oldham; J McCullough
Journal:  Transfusion       Date:  1996-07       Impact factor: 3.157

10.  Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor.

Authors:  C Shimazaki; N Oku; E Ashihara; K Okawa; H Goto; T Inaba; K Ito; N Fujita; H Tsuji; S Murakami
Journal:  Bone Marrow Transplant       Date:  1992-10       Impact factor: 5.483

View more
  3 in total

1.  Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.

Authors:  Qiuyan Liu; Ha Zhu; Chaoxiong Zhang; Taoyong Chen; Xuetao Cao
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

2.  Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma.

Authors:  Rosamaria Tedeschi; Ettore Bidoli; Maria Teresa Bortolin; Ornella Schioppa; Emanuela Vaccher; Paolo De Paoli
Journal:  Oncotarget       Date:  2015-10-06

Review 3.  The Effect of Granulocyte Colony-Stimulating Factor on the Progression of Atherosclerosis in Animal Models: A Meta-Analysis.

Authors:  Manli Liu; Kejian Liu; Dongdong Chen; Hongzhi Chen; Kunming Sun; Xinxin Ju; Jiaojiao Lan; Yang Zhou; Weishan Wang; Lijuan Pang
Journal:  Biomed Res Int       Date:  2017-09-12       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.